Home / Precision Medicine (page 28)

Precision Medicine

RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …

Read More »

Amgen’s deCODE Genetics Study Reveals Clues to Disease-Causing Genes

Amgen’s deCODE Genetics published four landmark papers built on whole-genome sequence data from more than 100,000 people from across Iceland. Research groups led by scientists from Amgen’s deCODE Genetics reported data that comprise the largest set of human genome sequenced from a single population in Nature Genetics. Four separate papers …

Read More »

Drug Companies Join Initiative to Decode 100,000 Human Genomes

A group of leading drugmakers have joined Genomics England in a new collaboration as part of the 100,000 Genomes Project, aimed at accelerating the development of new drugs and diagnostics. Ten biopharma companies have joined together to create the Genomics Expert Network for Enterprises (GENE) Consortium, to oversee a year-long …

Read More »

AstraZeneca and Harvard Stem Cell Institute Team Up for Diabetes Research

AstraZeneca inked a five-year research deal with Harvard Stem Cell Institute (HSCI) for new treatments for diabetes. The company announced today that it has entered into a five-year research collaboration with HSCI to adapt a technique that creates human beta cells from stem cells for use in screens for AstraZeneca’s …

Read More »

VBL Therapeutics’ Experimental Brain Cancer Drug Improves Survival in Phase 2 Study

Israel’s VBL Therapeutics said that its experimental brain cancer drug met the main goal of improving overall survival in a mid-stage study. The company announced top-line interim results from its ongoing Phase II study of investigational VB-111 in patients with recurrent glioblastoma (rGBM). According to VBL, the drug demonstrated a …

Read More »

Merck’s Keytruda Tops Yervoy in Head-to-Head Melanoma Trial

Merck’s Keytruda (pembrolizumab) beat out Bristol-Myers Squibb’s Yervoy (ipilimumab) in a late-stage, head-to-head trial in patients with advanced melanoma. The company announced today that Keytruda demonstrated superior overall survival (OS) and progression-free survival (PFS) compared to Yervoy in its Phase III study, known as KEYNOTE-006, in the first-line treatment of …

Read More »

Cypher Genomics’ New Technology Addresses Major Obstacle in Personalized Medicine for Cancer

A major bottleneck for realizing personalized medicine in cancer is understanding the clinical importance of tumor-specific genomic alterations, according to genome informatics company, Cypher Genomics, Inc. In an effort to address this challenge, the San Diego-based company announced that it has released a new software update to automate the interpretation …

Read More »

ImmunoGen Licenses ADC Technology to Takeda for Development of Cancer Drugs

Oncology biotech ImmunoGen, Inc. announced that it has entered into a $440 million antibody-drug conjugate (ADC) licensing deal with Takeda Pharmaceutical Company Limited. Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. Under the deal, ImmunoGen …

Read More »

Amicus to Seek Accelerated US and European Approval of its Investigational Fabry Disease Drug

Amicus Therapeutics announced its plans to file for accelerated approval of its investigational drug for a rare, inherited disease, following meetings with regulators in the US and Europe. The company said that it has recently met with regulatory authorities in Europe and the US to discuss the approval pathways for …

Read More »

Vaccinex Enters Deal with Five Prime Therapeutics Utilizing Vaccinex’s Antibody Discovery Platform

Privately-held clinical-stage immunotherapy company, Vaccinex, Inc., recently announced that it has signed a multi-target antibody discovery deal with Five Prime Therapeutics. Vaccinex said that it has entered into a multi-target collaboration agreement with Five Prime to utilize Vaccinex’s ActivMab antibody discovery platform for the discovery of monoclonal antibodies against novel …

Read More »